289 related articles for article (PubMed ID: 26047654)
1. Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy.
Kadono Y; Nohara T; Ueno S; Izumi K; Kitagawa Y; Konaka H; Mizokami A; Onozawa M; Hinotsu S; Akaza H; Namiki M
World J Urol; 2016 Feb; 34(2):261-7. PubMed ID: 26047654
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
Kitagawa Y; Ueno S; Izumi K; Kadono Y; Mizokami A; Hinotsu S; Akaza H; Namiki M
World J Urol; 2016 Mar; 34(3):319-27. PubMed ID: 26089252
[TBL] [Abstract][Full Text] [Related]
3. Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy.
Wang Y; Xu F; Pan J; Zhu Y; Shao X; Sha J; Wang Z; Cai Y; Liu Q; Dong B; Xue W; Huang Y
BMC Cancer; 2016 May; 16():329. PubMed ID: 27222030
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment plasma fibrinogen as an independent prognostic indicator of prostate cancer patients treated with androgen deprivation therapy.
Wang Y; Yin W; Wang Z; Huang J; Pan J; Zhu Y; Xu F; Shao X; Sha J; Cai Y; Liu Q; Dong B; Xue W; Huang Y
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):209-15. PubMed ID: 26951714
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
[TBL] [Abstract][Full Text] [Related]
6. Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.
Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
BMC Cancer; 2015 May; 15():420. PubMed ID: 25990314
[TBL] [Abstract][Full Text] [Related]
7. Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
Kitagawa Y; Hinotsu S; Shigehara K; Nakashima K; Kawaguchi S; Yaegashi H; Mizokami A; Akaza H; Namiki M
Int J Urol; 2013 Jul; 20(7):708-14. PubMed ID: 23216462
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer.
Matsuoka T; Kawai K; Kimura T; Kojima T; Onozawa M; Miyazaki J; Nishiyama H; Hinotsu S; Akaza H
J Cancer Res Clin Oncol; 2015 Apr; 141(4):759-65. PubMed ID: 25326347
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients.
Rii J; Sakamoto S; Yamada Y; Takeshita N; Yamamoto S; Sazuka T; Imamura Y; Nakamura K; Komiya A; Komaru A; Fukasawa S; Nakatsu H; Akakura K; Ichikawa T
Prostate; 2020 Aug; 80(11):850-858. PubMed ID: 32501559
[TBL] [Abstract][Full Text] [Related]
10. Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP).
Kitagawa Y; Ueno S; Izumi K; Mizokami A; Hinotsu S; Akaza H; Namiki M
J Cancer Res Clin Oncol; 2014 Apr; 140(4):673-9. PubMed ID: 24522405
[TBL] [Abstract][Full Text] [Related]
11. Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy.
Narita S; Nomura K; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nagashima K; Habuchi T
Cancer Med; 2019 Nov; 8(15):6566-6577. PubMed ID: 31508900
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
13. Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification.
Choi SY; Ryu J; You D; Hong JH; Ahn H; Kim CS
Int J Urol; 2019 Jan; 26(1):62-68. PubMed ID: 30238513
[TBL] [Abstract][Full Text] [Related]
14. Whole pelvis radiotherapy for pathological node-positive prostate cancer : Oncological outcome and prognostic factors.
Poelaert F; Fonteyne V; Ost P; De Troyer B; Decaestecker K; De Meerleer G; De Visschere P; Claeys T; Dhondt B; Lumen N
Strahlenther Onkol; 2017 Jun; 193(6):444-451. PubMed ID: 28101585
[TBL] [Abstract][Full Text] [Related]
15. The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy.
Qian Y; Feng FY; Halverson S; Blas K; Sandler HM; Hamstra DA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e135-42. PubMed ID: 21345617
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan.
Narita S; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Koizumi A; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nomura K; Habuchi T
Int J Clin Oncol; 2020 May; 25(5):912-920. PubMed ID: 31919691
[TBL] [Abstract][Full Text] [Related]
17. Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis.
Sasaki T; Onishi T; Hoshina A
Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):248-52. PubMed ID: 21502970
[TBL] [Abstract][Full Text] [Related]
18. The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy.
Shiota M; Yokomizo A; Takeuchi A; Imada K; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
J Cancer Res Clin Oncol; 2015 Mar; 141(3):495-503. PubMed ID: 25227457
[TBL] [Abstract][Full Text] [Related]
19. Validation of the prognostic grouping of the seventh edition of the tumor-nodes-metastasis classification using a large-scale prospective cohort study database of prostate cancer treated with primary androgen deprivation therapy.
Kimura T; Onozawa M; Miyazaki J; Kawai K; Nishiyama H; Hinotsu S; Akaza H
Int J Urol; 2013 Sep; 20(9):880-8. PubMed ID: 23347189
[TBL] [Abstract][Full Text] [Related]
20. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
